MedTrace Logo

Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction

NCT02075125 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2017-08-18

Study results available
· View outcomes & findings →

Summary

To compare efficacy and safety of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Conditions

  • ST-Segment Elevation Myocardial Infarction

Interventions

DRUG

Prasugrel 60 mg

Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.

DRUG

Ticagrelor 180 mg

Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.

Sponsors & Collaborators

  • Dong-A University

    lead OTHER

Principal Investigators

  • Moo Hyun Kim, M.D. · Dong-A University Hospital, Busan, Republic of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02075125 on ClinicalTrials.gov